Jenkins John Kenneth 4

What Happened

• John Kenneth Jenkins, a director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), received equity awards on May 19, 2026: 3,800 restricted stock units (RSUs) and 12,300 derivative securities reported as an award. Both awards show an acquisition price of $0.00 (total reported value $0) and vest 100% on the one‑year anniversary of the grant.

Key Details

• Transaction date: May 19, 2026; Form 4 filed May 21, 2026 (appears timely).
• Awards: 3,800 RSUs (to be settled in common stock) and 12,300 derivative awards (reported as derivative/option awards under issuer’s 2024 Equity Compensation Plan per footnote).
• Vesting: Both grants vest 100% one year from the grant date (May 19, 2027).
• Footnotes: The 3,800 RSUs were newly granted (F1). The 12,300 derivative amount includes 8,600 unvested RSUs previously reported (F2). The derivative/option award was made under the 2024 Equity Compensation Plan and vests in one year (F3).
• Shares owned after the transaction: not specified in the filing.

Context

• These are grant awards (not purchases or sales). RSUs convert to shares at settlement; derivative awards (options/other) will only result in shares if vested/exercised per their terms. Such grants are common for directors as part of compensation and do not, by themselves, indicate buying or selling sentiment.